Hubbard Radio Washington DC, LLC. All rights reserved. This website is not intended for users located within the European Economic Area.
ROCKVILLE, Md. (AP) _ Regenxbio Inc. (RGNX) on Monday reported a loss of $46.2 million in its fourth quarter.
On a per-share basis, the Rockville, Maryland-based company said it had a loss of $1.24.
The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.11 per share.
The biotechnology company posted revenue of $21.4 million in the period.
Insight by Workday: Human capital experts from DHS, Interior Department, GSA and Metropolitan Washington Airports Authority will describe the different stages of their IT modernization journeys in this free webinar.
Regenxbio shares have declined 6.5% since the beginning of the year. In the final minutes of trading on Monday, shares hit $42.43, a rise of roughly 5% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RGNX at https://www.zacks.com/ap/RGNX
Copyright © 2021 . All rights reserved. This website is not intended for users located within the European Economic Area.